Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
NeoGenomics Laboratories revenue
NeoGenomics Laboratories's revenue is $660.6 million.
What is NeoGenomics Laboratories's revenue?
- NeoGenomics Laboratories's revenue growth from 2010 to 2024 is 1,821.87%.
- NeoGenomics Laboratories has 1,500 employees, and the revenue per employee ratio is $440,377.
- NeoGenomics Laboratories's peak quarterly revenue was $172.0M in 2024(q4).
- NeoGenomics Laboratories peak revenue was $660.6M in 2024.
- NeoGenomics Laboratories annual revenue for 2023 was 591.6M, 16.07% growth from 2022.
- NeoGenomics Laboratories annual revenue for 2024 was 660.6M, 11.65% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
NeoGenomics Laboratories historical revenue
NeoGenomics Laboratories's peak revenue was $660.6M in 2024. The peak quarterly revenue was $172.0M in 2024(q4).
NeoGenomics Laboratories's revenue increased from $34.4m in 2010 to $660.6M currently. That's a 1,821.87% change in annual revenue.
NeoGenomics Laboratories annual revenue
NeoGenomics Laboratories annual revenue over time
| Fiscal year / year | NeoGenomics Laboratories revenue |
|---|---|
| 2010 | $34.4M |
| 2011 | $43.5M |
| 2012 | $59.9M |
| 2013 | $66.5M |
| 2014 | $87.1M |
| 2015 | $99.8M |
| 2016 | $231.8M |
| 2017 | $240.3M |
| 2018 | $276.7M |
| 2019 | $408.8M |
| 2020 | $444.4M |
| 2021 | $484.3M |
| 2022 | $509.7M |
| 2023 | $591.6M |
| 2024 | $660.6M |
Rate NeoGenomics Laboratories' financial transparency
NeoGenomics Laboratories annual growth
NeoGenomics Laboratories saw the greatest revenue growth in 2016, when revenue increased by 132.27%.
NeoGenomics Laboratories had the lowest revenue growth in 2017, when revenue changed by 3.64%.
NeoGenomics Laboratories annual growth rate over time
| Year | NeoGenomics Laboratories growth |
|---|---|
| 2011 | 27%↑ |
| 2012 | 38%↑ |
| 2013 | 11%↑ |
| 2014 | 31%↑ |
| 2015 | 15%↑ |
| 2016 | 132%↑ |
| 2017 | 4%↑ |
| 2018 | 15%↑ |
| 2019 | 48%↑ |
| 2020 | 9%↑ |
| 2021 | 9%↑ |
| 2022 | 5%↑ |
| 2023 | 16%↑ |
| 2024 | 12%↑ |
NeoGenomics Laboratories quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
NeoGenomics Laboratories quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $10.5M | $11.3M | $12.9M |
| 2012 | $15.2M | $15.6M | $14.2M | $14.9M |
| 2013 | $15.7M | $15.6M | $16.9M | $18.3M |
| 2014 | $18.2M | $20.7M | $23.2M | $25.0M |
| 2015 | $23.0M | $24.4M | $25.1M | $27.3M |
| 2016 | $59.7M | $63.1M | $60.8M | $48.2M |
| 2017 | $57.4M | $62.3M | $59.1M | $61.4M |
| 2018 | $63.4M | $67.7M | $69.1M | $76.5M |
| 2019 | $95.6M | $101.7M | $104.7M | $106.9M |
| 2020 | $106.0M | $87.0M | $125.4M | $126.0M |
| 2021 | $115.5M | $121.7M | $121.3M | $125.7M |
| 2022 | $117.2M | $125.1M | $128.8M | $138.7M |
| 2023 | $137.2M | $146.9M | $152.0M | $155.6M |
| 2024 | $156.2M | $164.5M | $167.8M | $172.0M |
NeoGenomics Laboratories jobs nearby
Do you work at NeoGenomics Laboratories?
Did NeoGenomics Laboratories meet its revenue projections?
NeoGenomics Laboratories financial information
| CEO | Lynn A. Tetrault - Executive Chair |
| Company Type | Public |
| Employees Number | 1,500 |
| Date Founded | 2001 |
| Headquarters | Fort Myers, Florida |
| Number of Locations | 11 |
| Revenue | $660.6M |
| Net Income | -$144,250,000 |
| Gross Proft | $290.1M (2024) |
| PE Ratio | -17.01 |
| Tax Rate | 0.0% |
| Market Capitalization | $1.3B |
| Total Assets | $1,740,034,000 |
| Ticker | NEO |
NeoGenomics Laboratories jobs you might like
NeoGenomics Laboratories financing
NeoGenomics Laboratories received early financing of $500.0K on 2009-03-30.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $500K | 03/2009 |
| Post Ipo Debt | $150M | 12/2016 |
| Post Ipo Equity | $200M | 05/2021 |
NeoGenomics Laboratories investors
| Investors | Security type |
|---|---|
| RTW Investments LLC | Post Ipo Equity |
| FIRST LIGHT ASSET MANAGEMENT | Post Ipo Equity |
| Woodline Partners LP | Post Ipo Equity |
| Avidity Partners | Post Ipo Equity |
| Soleus Capital LLC | Post Ipo Equity |
| Farallon Capital Management | Post Ipo Equity |
| DRIEHAUS CAPITAL MANAGEMENT | Post Ipo Equity |
| RS Investments | Post Ipo Equity |
| Federated Kaufmann Fund | Post Ipo Equity |
| Blue Water Life Science Fund LP | Post Ipo Equity |
| JANUS HENDERSON GROUP PLC | Post Ipo Equity |
| Casdin Capital | Post Ipo Equity |
| Pura Vida Investments | Post Ipo Equity |
NeoGenomics Laboratories competitors
NeoGenomics Laboratories's top competitor, Vertex Pharmaceuticals, earned an annual revenue of $11.0B.
NeoGenomics Laboratories's smallest competitor is Epic Sciences with revenue of $1.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Foundation Medicine | $94,749 | $152.9M | 1,300 | 49 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 25 |
| BioReliance | $74,348 | $49.9M | 700 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Lineagen | $50,284 | $3.0M | 52 | - |
| Intellia Therapeutics | $79,975 | $57.9M | 211 | 19 |
| Epic Sciences | $45,673 | $1.0M | 10 | 5 |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Genoptix | $60,009 | $198.1M | 440 | - |
NeoGenomics Laboratories revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
NeoGenomics Laboratories highest paying jobs
Zippia gives an in-depth look into the details of NeoGenomics Laboratories, including salaries, political affiliations, employee data, and more, in order to inform job seekers about NeoGenomics Laboratories. The employee data is based on information from people who have self-reported their past or current employments at NeoGenomics Laboratories. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by NeoGenomics Laboratories. The data presented on this page does not represent the view of NeoGenomics Laboratories and its employees or that of Zippia.
NeoGenomics Laboratories may also be known as or be related to NEOGENOMICS INC, NeoGenomics, NeoGenomics Inc, NeoGenomics Laboratories, NeoGenomics Laboratories, Inc., NeoGenomics, Inc., Neogenomics Laboratories and Neogenomics, Inc.